Immunizing Your Adult Patients
Which of the following is TRUE with regards to using adjuvants in vaccinations?
Adjuvants are newer technology only utilized within the last 30 years
Adjuvants (such as MF59) target a specific component of the immune system to promote a stronger immune response
Adjuvant technology has shown no benefit in the elderly
Adjuvants lower the risk of allergic reactions to vaccines
Vaccines containing adjuvants tend to have less side effects
Which of the following is TRUE with regards to vaccinations and "Shared Clinical Decision-Making"?
Involves coordination with both patients and their insurance carrier to ensure coverage of immunizations at the time of service
Involves the collaboration between various medical providers to implement overall "best practices" guidance on immunization recommendations
Centers the conversation around the needs/wishes of the patient such that they can make an informed decision regarding vaccination
Is the process by which the FDA comes to a consensus on yearly immunization recommendations
Based on the 2021 ACIP Recommended Adult Immunization Schedule, which of the following is TRUE with respect to Zoster Vaccination?
You do not need to administer Recombinant Zoster Vaccine (RZV brand name Shingrix) if a patient has previously received Zoster Vaccine Live (ZVL brand name Zostavax)
Patients should receive either RZV or ZVL
If someone has already had a Zoster outbreak, they do not need to be vaccinated
ZVL has been removed from the list of vaccination options